Summary of key recommendations: Difference between revisions
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults== | ==Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults== | ||
A. Heart-healthy lifestyle habits should be encouraged for all individuals | |||
{|class="wikitable" style="width:80%" | {|class="wikitable" style="width:80%" | ||
|- | |- | ||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Clinical ASCVD | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Clinical ASCVD which includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | ||
*Age 75 y and no safety concerns: High-intensity statin. | |||
*Age >75 y or safety concerns: Moderate-intensity statin. | *Age >75 y or safety concerns: Moderate-intensity statin. | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.'''Primary prevention – Primary LDL-C ‡190 mg/dL''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.'''Primary prevention – Primary LDL-C ‡190 mg/dL ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
*Rule out secondary causes of hyperlipidemia | *Rule out secondary causes of hyperlipidemia | ||
*Age !21 y: High-intensity statin | *Age !21 y: High-intensity statin | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.'''Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.'''Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | ||
*Moderate-intensity statin | |||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.''' Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.''' Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | ||
*Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equationsy in those NOT receiving a statin; estimate risk every 4–6 y''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | *Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equationsy in those NOT receiving a statin; estimate risk every 4–6 y ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
*Re-emphasize heart-healthy lifestyle habits and address other risk factors | |||
** ‡7.5% 10-y ASCVD risk: Moderate- or high-intensity statin ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.''' | |||
|- | |- | ||
Revision as of 18:08, 27 October 2016
Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
A. Heart-healthy lifestyle habits should be encouraged for all individuals
| Class I |
"1.Clinical ASCVD which includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin (Level of Evidence: A) "
|
"2.Primary prevention – Primary LDL-C ‡190 mg/dL (Level of Evidence: B) "
|
"3.Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL (Level of Evidence: A) "
|
"4. Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL (Level of Evidence: C) "
|
| "4. |
| Class III (Harm) |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class III (No Benefit) |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class IIa |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class IIb |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |